Your browser doesn't support javascript.
loading
DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma.
Olsen, Thale Kristin; Dyberg, Cecilia; Embaie, Bethel Tesfai; Alchahin, Adele; Milosevic, Jelena; Ding, Jane; Otte, Jörg; Tümmler, Conny; Hed Myrberg, Ida; Westerhout, Ellen M; Koster, Jan; Versteeg, Rogier; Ding, Han-Fei; Kogner, Per; Johnsen, John Inge; Sykes, David B; Baryawno, Ninib.
Affiliation
  • Olsen TK; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Dyberg C; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Embaie BT; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Alchahin A; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Milosevic J; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Ding J; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Otte J; Division of Molecular and Cellular Pathology, Department of Pathology, Heersink School of Medicine, the University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Tümmler C; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Hed Myrberg I; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Westerhout EM; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Koster J; Department of Oncogenomics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Versteeg R; Department of Oncogenomics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Ding HF; Department of Oncogenomics, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Kogner P; Division of Molecular and Cellular Pathology, Department of Pathology, Heersink School of Medicine, the University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Johnsen JI; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Sykes DB; Division of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Baryawno N; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
JCI Insight ; 7(17)2022 08 09.
Article in En | MEDLINE | ID: mdl-35943801
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxidoreductases Acting on CH-CH Group Donors / Neuroblastoma Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: JCI Insight Year: 2022 Document type: Article Affiliation country: Sweden Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxidoreductases Acting on CH-CH Group Donors / Neuroblastoma Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: JCI Insight Year: 2022 Document type: Article Affiliation country: Sweden Country of publication: United States